Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01422148 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac Surgery

Study acronym: MINA
StatusWithdrawn
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Withdrawn before enrolling Sponsor's reason: NOT ENOUGH PARTICIPANTS Show 4 more changesShow less
    • Enrollment target: estimated 60 to confirmed 0
    • Start date changed from estimate of Jul 2025 to Sep 3, 2025
    • Eligibility criteria revised
    • Site contact updated
  2. Start date: Feb 2024 to Jul 2025v17
  3. Secondary endpoints: details revised at 1 of 3 entries
    • Eligibility criteria expanded, about 3 words
    v16
  4. Primary completion date: Jan 24, 2025 to Jan 24, 2027v15 Show 4 more changesShow less
    • Start date: Feb 2023 to Feb 2024
    • Primary endpoint revised
    • Study completion date: Jan 24, 2026 to Jan 24, 2028
    • Secondary endpoints: 1 to 3
  5. Start date: Jan 25, 2022 to Feb 2023
    • Study site revised
    v14
Show 12 earlier versionsHide 12 earlier versions
  1. Primary completion date: May 15, 2023 to Jan 24, 2025
    • Start date: May 16, 2020 to Jan 25, 2022
    • Study completion date: May 15, 2023 to Jan 24, 2026
    v13
  2. Primary and study completion dates: Jan 2022 to May 15, 2023v12 Show 7 more changesShow less
    • Primary endpoint revised
    • Trial status: Recruiting to Not Yet Recruiting
    • Start date: May 2020 to May 16, 2020
    • Eligibility criteria expanded, about 80 words
    • Study description expanded, about 29 words
    • Site details revised
    • Secondary endpoints expanded, about 2 words
  3. Phase: Not applicable to Phase 2v11 Show 4 more changesShow less
    • Enrollment target: 40 to 60
    • Primary completion date: Jan 2019 to Jan 2022
    • Start date: Oct 2011 to May 2020
    • Study completion date: Jan 2020 to Jan 2022
  4. Primary completion date: Jan 2018 to Jan 2019
    • Study completion date: Mar 2018 to Jan 2020
    v10
  5. Primary completion date: Jan 2017 to Jan 2018
    • Study completion date: Mar 2017 to Mar 2018
    v9
  6. Re-verified, no change to tracked fieldsv8
  7. Trial status: Active, Not Recruiting to Recruitingv7 Show 4 more changesShow less
    • Enrollment target: 400 to 40
    • Primary completion date: Jul 2015 to Jan 2017
    • Study completion date: Jul 2015 to Mar 2017
    • Site details revised
  8. Primary completion date: Oct 2014 to Jul 2015
    • Study completion date: Dec 2014 to Jul 2015
    v6
  9. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v5
  10. Primary completion date: Oct 2013 to Oct 2014
    • Study completion date: Dec 2013 to Dec 2014
    v4
  11. Re-verified, no change to tracked fieldsv3
  12. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
. New- onset postoperative atrial fibrillation (POAF) is a common complication after cardiac surgery and its occurrence increases with age. POAF can result in clinically significant morbidity and mortality. The national trend in the US is that the population older than 65 years is increasing, making healthcare expenditure related to POAF to be a major burden on health care system. Effective treatment of POAF is imperative in ensuring quality of care and reduction of costs. In 2021 there is a projected total of 377,763 cardiovascular surgeries in the US alone with approximately half of which will have POAF with longer postoperative length of stay (+3.9 days) and higher discharge costs (+$13,993) than no-POAF patients (Reference: Ann Thorac Surg. 2015 Jan;99(1):109-14). Amiodarone, the currently used therapy, is often insufficient to prevent POAF and has multiple side-effects. In this study, we expect to improve the incidence of POAF by using a common acne drug (Minocycline) that is safe and that could be incorporated in clinical care of this disease.
Trial Details
NCT Number NCT01422148
Lead Sponsor Baystate Medical Center
Conditions
(from sponsor)		 Atrial Fibrillation
Related terms Atrial Fibrillation, cyclopia sequence
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov